First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study

BACKGROUND: There have been no comprehensive large-scale studies that have evaluated the benefits of chemotherapy-based regimens in addressing HER2-altered advanced non-small-cell lung cancer (NSCLC) in a first-line setting. Data on HER2 alteration subtypes and concomitant alterations are also limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Guangjian, Yang, Yaning, Liu, Runze, Li, Weihua, Xu, Haiyan, Hao, Xuezhi, Li, Junling, Xing, Puyuan, Zhang, Shuyang, Ai, Xin, Xu, Fei, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894956/
https://www.ncbi.nlm.nih.gov/pubmed/35251321
http://dx.doi.org/10.1177/17588359221082339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894956/
https://www.ncbi.nlm.nih.gov/pubmed/35251321
http://dx.doi.org/10.1177/17588359221082339

Ejemplares similares